Renovaro signs MoU with Amsterdam UMC to form joint cancer immunotherapy company

Lunai Bioworks Inc.

Signed MoU to establish Newco in Netherlands for personalized cancer immunotherapy.
Combines Renovaro's proprietary dendritic vaccine tech with Amsterdam UMC's immunomodulatory expertise.
Newco to be headquartered in Amsterdam; clinical activities may move there.
Final commitments subject to due diligence and approval from both executive boards.
No financial terms or deal value disclosed in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.